Filip E Van den Bosch (Filip Van den Bosch, Filip van den Bosch)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 38

Top Topics

Rheumatoid Arthritis

Top Venues

Annals of the rheumatic diseases

The Journal of rheumatology

Rheumatology and therapy

ACR open rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Gerd-Rüdiger R Burmester, Filip E Van den Bosch, Diamant Thaҫi, Anna K Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan J Kivitz
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of rheumatology 51 (7) (2024)
Filip E Van den Bosch, Atul A Deodhar, Denis Poddubnyy, Walter P Maksymowych, Désirée Mfm van der Heijde, Tae Hwan Kim, Kishimoto Mitsumasa, Xenofon Baraliakos, Yihan Li, Kristin M D'Silva, Peter Wung, In-Ho Song
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. ACR open rheumatology 6 (8) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy (2024)
Filip E Van den Bosch, Atul A Deodhar, Denis Poddubnyy, Walter P Maksymowych, Désirée Mfm van der Heijde, Tae Hwan Kim, Kishimoto Mitsumasa, Xenofon Baraliakos, Yihan Li, Kristin M D'Silva, Peter Wung, In-Ho Song
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. ACR open rheumatology 6 (8) (2024)
Sophie De Mits, Tine Marieke Willems, Patrick Calders, Lieven Danneels, Gaëlle Varkas, Filip E Van den Bosch, Dirk Elewaut, Philippe Carron
Maximal Exercise Tolerance, Objective Trunk Strength, and Mobility Measurements in Axial Spondyloarthritis. The Journal of rheumatology 51 (6) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Filip E Van den Bosch, Atul A Deodhar, Denis Poddubnyy, Walter P Maksymowych, Désirée Mfm van der Heijde, Tae Hwan Kim, Kishimoto Mitsumasa, Xenofon Baraliakos, Yihan Li, Kristin M D'Silva, Peter Wung, In-Ho Song
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. ACR open rheumatology (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Filip E Van den Bosch, Atul A Deodhar, Denis Poddubnyy, Walter P Maksymowych, Désirée Mfm van der Heijde, Tae Hwan Kim, Kishimoto Mitsumasa, Xenofon Baraliakos, Yihan Li, Kristin M D'Silva, Peter Wung, In-Ho Song
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. ACR open rheumatology 6 (8) (2024)
Clementina López Medina, Filip E Van den Bosch, Désirée Mfm van der Heijde, Maxime Dougados, Anna Moltó
When Usual Care Is Not So Usual: Protocol Violations and Generalizability in a Treat-to-Target Strategy Trial in Patients With Axial Spondyloarthritis. Arthritis care & research (2024)
Gerd-Rüdiger R Burmester, Filip E Van den Bosch, Diamant Thaҫi, Anna K Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan J Kivitz
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of rheumatology 51 (7) (2024)
Sophie De Mits, Tine Marieke Willems, Patrick Calders, Lieven Danneels, Gaëlle Varkas, Filip E Van den Bosch, Dirk Elewaut, Philippe Carron
Maximal Exercise Tolerance, Objective Trunk Strength, and Mobility Measurements in Axial Spondyloarthritis. The Journal of rheumatology (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Gerd-Rüdiger R Burmester, Filip E Van den Bosch, Diamant Thaҫi, Anna K Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan J Kivitz
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of rheumatology (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Désirée Mfm van der Heijde, Atul A Deodhar, Xenofon Baraliakos, Matthew A Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S Gensler, Nigil Haroon, Marina Magrey, Walter P Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip E Van den Bosch, Thomas Vaux, Huji Xu
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the rheumatic diseases (2023)
Alen Zabotti, Gabriele De Marco, Laure Gossec, Xenofon Baraliakos, Daniel Aletaha, AnnaMaria Iagnocco, Paolo Gisondi, Peter V Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Nemanja S Damjanov, Maarten P T de Wit, Enzo Errichetti, Helena Marzo-Ortega, Mikhail Protopopov, Lluis Puig, Rubén Queiro, Roberto Caporali, Laura Savage, Larissa Valor-Méndez, Stefan Siebert, Tanja Alexandra Stamm, Paul Studenic, Ilaria Tinazzi, Filip E Van den Bosch, Annette van der Helm-van Mil, Giovanni Damiani, Josef S Smolen, Dennis G McGonagle
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Annals of the rheumatic diseases (2023)
Désirée Mfm van der Heijde, Anna Moltó, Josef S Smolen, Jüergen Braun, Maxime Dougados, Floris A van Gaalen, Lianne S Gensler, Robert Davies Inman, Robert B M Landewe, Helena Marzo-Ortega, Victoria Navarro-Compán, Andri Phoka, Denis Poddubnyy, Mikhail Protopopov, John D Reveille, Martin Rudwaleit, Percival Sampaio-Barros, Alexandre Sepriano, Joachim Sieper, Filip E Van den Bosch, Irene van der Horst-Bruinsma, Pedro M Machado, Xenofon Baraliakos
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature. Annals of the rheumatic diseases (2023)
Manouk de Hooge, Alla Ischenko, Serge Steinfeld, Adrien Nzeusseu, Dirk Elewaut, Rik Ju Lories, Filip E Van den Bosch, Kurt De Vlam
Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patients. Annals of the rheumatic diseases (2023)
Désirée Mfm van der Heijde, Atul A Deodhar, Xenofon Baraliakos, Matthew A Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S Gensler, Nigil Haroon, Marina Magrey, Walter P Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip E Van den Bosch, Thomas Vaux, Huji Xu
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the rheumatic diseases (2023)
Koen Venken, Matthias Jarlborg, Tine Decruy, Céline Mortier, Carolien Vlieghe, Elisabeth Gilis, Ann-Sophie De Craemer, Julie Coudenys, Isabelle Cambré, Devan Fleury, Alexander Klimowicz, Filip E Van den Bosch, Anne Hoorens, Triana Lobaton, Sytze de Roock, Tim Sparwasser, Gerald Nabozny, Peggy Jacques, Dirk Elewaut
Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis. Annals of the rheumatic diseases (2023)
Victoria Navarro-Compán, Diego Benavent, Dafne Capelusnik, Désirée Mfm van der Heijde, Robert B M Landewe, Denis Poddubnyy, Astrid van Tubergen, Xenofon Baraliakos, Filip E Van den Bosch, Floris A van Gaalen, Lianne S Gensler, Clementina López Medina, Helena Marzo-Ortega, Anna Moltó, Rodolfo Pérez-Alamino, Martin Rudwaleit, Marleen van de Sande, Alice Heaney, Ulrich Weber, Josef S Smolen
ASAS consensus definition of early axial spondyloarthritis. Annals of the rheumatic diseases (2023)
Robert B M Landewe, Denis Poddubnyy, Proton Rahman, Filip E Van den Bosch, Rebecca Bolce, Soyi Liu Leage, Jeffrey R Lisse, So Young Park, Lianne Gensler
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study. Annals of the rheumatic diseases (2022)
Josef S Smolen, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B M Landewe, Filip E Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris A van Gaalen, Pál Géher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina López Medina, Pedro M Machado, Helena Marzo-Ortega, Anna Moltó, Victoria Navarro-Compán, Michael John Nissen, Fernando M Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziadé, Désirée Mfm van der Heijde
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the rheumatic diseases (2022)
Robert B M Landewe, Lianne S Gensler, Denis Poddubnyy, Proton Rahman, Maja Hojnik, Xiaoqi Li, Soyi Liu Leage, David Adams, Hilde Carlier, Filip E Van den Bosch, null null
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Annals of the rheumatic diseases (2021)
Anna Moltó, Désirée Mfm van der Heijde, Filip E Van den Bosch, Maxime Dougados
Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng. Annals of the rheumatic diseases (2021)
Phillip J Mease, Filip E Van den Bosch
IL-23 and axial disease: do they come together? Rheumatology (Oxford, England) 60 (Suppl 4) (2021)
Anna Moltó, Clementina López Medina, Filip E Van den Bosch, Annelies Boonen, Casper Webers, Emanuelle Dernis, Floris A van Gaalen, Martin Soubrier, Pascal Claudepierre, Athan Baillet, Mirian Starmans-Kool, Anneke Spoorenberg, Peggy Jacques, Philippe Carron, Rik Joos, Jan Lenaerts, Laure Gossec, Sophie Pouplin, Adeline Ruyssen-Witrand, Laetitia Sparsa, Astrid van Tubergen, Désirée Mfm van der Heijde, Maxime Dougados
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Annals of the rheumatic diseases 80 (11) (2021)
Frank Behrens, Soyi Liu Leage, Christophe Sapin, Celine El Baou, Inmaculada De La Torre, Gabriella Meszaros, Larissa Valor-Méndez, Bernard G Combe, Filip E Van den Bosch, Laure Gossec
Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Clinical rheumatology 40 (12) (2021)
Sophie De Mits, Ann-Sophie De Craemer, Liselotte Deroo, Thomas Renson, Filip E Van den Bosch, Philippe Carron, Dirk Elewaut
Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondyloarthritis. Annals of the rheumatic diseases 80 (12) (2021)
Uta Kiltz, Annelies Boonen, Désirée Mfm van der Heijde, Wilson Bautista Molano, Ruben Burgos Vargas, Praveena Chiowchanwisawakit, Bassel El-Zorkany, Inna Gaydukova, Pal Geher, Laure Gossec, Michele Gilio, Simeon Grazio, Jieruo Gu, Muhammad Asim Khan, Tae Jong Kim, Walter P Maksymowych, Helena Marzo-Ortega, Victoria Navarro-Compán, Salih Ozgocmen, Dimos Patrikos, Fernando Manuel Pimentel-Santos, John Reveille, Schirmer Michael, Simon Stebbings, Filip E Van den Bosch, Ulrich Weber, Juergen Braun
Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis. Rheumatology (Oxford, England) (2021)
Andrew Östör, Filip E Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Alan Kivitz
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Annals of the rheumatic diseases (2021)
Uta Kiltz, James Cheng-Chung Wei, Désirée Mfm van der Heijde, Filip E Van den Bosch, Jessica A Walsh, Annelies Boonen, Lianne S Gensler, Theresa Hunter, Hilde Carlier, Yan Dong, Xiaoqi Li, Rebecca Bolce, Vibeke Strand, Jüergen Braun
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. The Journal of rheumatology 48 (2) (2020)